Apremilast

Phosphodiesterase 4 Inhibitor — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Apremilast is an ofp drug in the Phosphodiesterase 4 Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2014. Its mechanism of action is classified as Phosphodiesterase 4 Inhibitors. DrugCentral lists 4 molecular targets, including PDE4A, PDE4B and PDE4D. Recorded indications include Behçet's disease affecting oral mucosa, Plaque psoriasis and Psoriasis with arthropathy.

• Approval status: ofp (first approved 2014 by the FDA).
• Drug class: Phosphodiesterase 4 Inhibitor.
• Mechanism of action: Phosphodiesterase 4 Inhibitors.
• Molecular targets: PDE4A, PDE4B, PDE4D and PDE4C (4 listed in DrugCentral).
• Indications: Behçet's disease affecting oral mucosa, Plaque psoriasis and Psoriasis with arthropathy.
• ATC code: L04AA32 (Selective immunosuppressants).
• Molecular formula: C22H24N2O7S; molecular weight 460.51 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (3)

• Behçet's disease affecting oral mucosa
• Plaque psoriasis
• Psoriasis with arthropathy

Mechanism & targets

• Mechanism of action (MoA): Phosphodiesterase 4 Inhibitors
• Established pharmacologic class: Phosphodiesterase 4 Inhibitor

Molecular targets (4)

Target	Gene	Action	Activity
cAMP-specific 3',5'-cyclic phosphodiesterase 4A	PDE4A	inhibitor	IC50 7.85
cAMP-specific 3',5'-cyclic phosphodiesterase 4B	PDE4B	inhibitor	IC50 7.57
cAMP-specific 3',5'-cyclic phosphodiesterase 4D	PDE4D	inhibitor	IC50 7.13
cAMP-specific 3',5'-cyclic phosphodiesterase 4C	PDE4C	inhibitor	IC50 6.93

Regulatory approvals (3)

Date	Agency	Marketed as	Applicant	Orphan
2019-09-20	PMDA	—	Celgene K.K.
2014-11-20	EMA	—	—
2014-03-21	FDA	—	CELGENE CORP

ATC classification

ATC code	Therapeutic hierarchy
L04AA32	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSUPPRESSANTS › IMMUNOSUPPRESSANTS › Selective immunosuppressants

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Diarrhoea	13138.7
Product dose omission issue	9582.9
Nausea	9105.4
Headache	8173.3
Abdominal discomfort	3707.3
Therapy non-responder	2825.3
Psoriatic arthropathy	2459.0
Depression	2213.9
Adverse drug reaction	2108.4
Acute kidney injury	2041.7
Drug ineffective	1895.0
Toxicity to various agents	1622.4

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Apremilast is on its molecule page.

• Molecular formula: C₂₂H₂₄N₂O₇S
• Molecular weight: 460.51 g/mol
• CAS number: —
• InChIKey: IMOZEMNVLZVGJZ-QGZVFWFLSA-N
• PubChem CID: 11561674

CCOC1=C(OC)C=CC(=C1)[C@@H](CS(C)(=O)=O)N1C(=O)C2=CC=CC(NC(C)=O)=C2C1=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Apremilast used for?

DrugCentral lists the following indications for Apremilast: Behçet's disease affecting oral mucosa, Plaque psoriasis and Psoriasis with arthropathy.

How does Apremilast work?

Apremilast is classified as Phosphodiesterase 4 Inhibitors; its molecular targets in DrugCentral include PDE4A (inhibitor), PDE4B (inhibitor), PDE4D (inhibitor) and PDE4C (inhibitor).

When was Apremilast first approved?

Apremilast was first approved by the FDA in 2014.

What drug class does Apremilast belong to?

Apremilast is in the Phosphodiesterase 4 Inhibitor class.

What is the chemical formula of Apremilast?

Apremilast has the molecular formula C22H24N2O7S and a molecular weight of 460.51 g/mol.

Sources

• DrugCentral drug card 4829 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL514800 — compound record and bioactivity
• PubChem CID 11561674 — chemical identifiers
• DrugBank DB05676 — drug record
• FDA UNII UP7QBP99PN — substance identity
• DailyMed: FDA labels for Apremilast — current prescribing information (label search)
• UniProt P27815 (PDE4A) — target protein
• UniProt Q07343 (PDE4B) — target protein
• UniProt Q08499 (PDE4D) — target protein
• UniProt Q08493 (PDE4C) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.